



WA Meningococcal ACWY Government Funded Program

Eligibility	Age at commencement of vaccine course	Vaccine brand	Dosing guidance for healthy people*
Aboriginal children (6 weeks to 11 months)	6 weeks–5months	Nimenrix Menveo	3 doses (8 weeks between 1st and 2nd doses; 3rd dose at 12 months of age)
	6–11 months	Nimenrix Menveo	2 doses (2nd dose at 12 months of age or 8 weeks after 1st dose, whichever is later)
All children (12 months)	12 months	Nimenrix	1 dose
All children (13 months to <5 years)	≥ 13 months	Nimenrix	1 dose (Administer only if 12 month scheduled dose not received)
Adolescents (15 to 19 years)	15-19 years	Nimenrix or Menveo	1 dose

Notes:

- *Please note that children with specified medical conditions that are associated with an increased risk of meningococcal disease usually require additional doses of Men ACWY vaccine. For more details on recommendations for children at increased risk of IMD, please check the Australian Immunisation Handbook immunisationhandbook.health.gov.au
- Men ACWY vaccines can be co-administered with other scheduled NIP vaccines. If not co-administering, the Men ACWY vaccine should be given at least 4 weeks later
- There should be a minimum interval of 8 weeks between Men ACWY doses.
- It is preferable to use the same brand of Men ACWY vaccines when giving subsequent doses, especially for completing the primary vaccination course for young children. However, a different brand may be substituted in cases where the initial brand is unavailable or unknown.